Optically-guided frameless linac-based radiosurgery for brain metastases: clinical experience by Nath, Sameer K. et al.
CLINICAL STUDY - PATIENT STUDY
Optically-guided frameless linac-based radiosurgery for brain
metastases: clinical experience
Sameer K. Nath Æ Joshua D. Lawson Æ Jia-Zhu Wang Æ
Daniel R. Simpson Æ C. Benjamin Newman Æ
John F. Alksne Æ Arno J. Mundt Æ Kevin T. Murphy
Received: 1 June 2009/Accepted: 9 August 2009/Published online: 23 August 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract The purpose of this study was to describe our
clinical experience using optically-guided linear accelera-
tor (linac)-based frameless stereotactic radiosurgery (SRS)
for the treatment of brain metastases. Sixty-ﬁve patients
(204 lesions) were treated between 2005 and 2008 with
frameless SRS using an optically-guided bite-block system.
Patients had a median of 2 lesions (range, 1–13). Pre-
scription dose ranged from 14 to 22 Gy (median, 18 Gy)
and was given in a single fraction. Clinical and radio-
graphic evaluation occurred every 2–4 months following
treatment. At a median follow-up of 6.2 months, actuarial
survival at 12 months was 40% [95% conﬁdence interval
(CI), 28–52). Of 135 lesions that were evaluable for local
control (LC), 119 lesions (88%) did not show evidence of
progression. Actuarial 12 month LC was 76% (95% CI,
66–86). Tumors B2 cm in size had a better 12 month LC
rate (81% vs. 36%, P = 0.017) than those[2 cm. Adverse
events occurred in three patients (5%). Optically-guided
linac-based frameless SRS can produce clinical outcomes
that compare favorably to frame-based techniques. As this
technique is convenient to use and allows for the uncom-
plicated delivery of hypofractionated radiotherapy, frame-
less SRS will likely have an increasingly important role in
the management of brain metastases.
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Introduction
Stereotactic radiosurgery (SRS) has a well-established role
for the treatment of intracranial disease and has been used
speciﬁcally for the management of brain metastases in the
United States since the mid 1980s [1]. The efﬁcacy of SRS
for the treatment of brain metastases has been demon-
strated in several randomized trials and multi-institutional
studies [2–5].
Conventionally, SRS is performed with the use of a
stereotactic head frame that is afﬁxed to the calvarium in
order to provide rigid patient immobilization during plan-
ning and treatment delivery. The use of a head frame in
SRS has been extensively studied and has been shown to be
associated with excellent target localization during both
planning and treatment delivery [6, 7]. However, although
this system provides a high-degree of accuracy that is
necessary when using large and highly-conformal doses,
there are several disadvantages of frame-based immobili-
zation, including patient discomfort, difﬁculty performing
hypofractionated therapy, and additional effort required to
coordinate between personnel on different services.
As an alternative to frame-based technologies, there is
now a variety of frameless systems that have been devised
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 (Accuray Inc., Sunnyvale, CA)
and traditional linear accelerator (linac)-based platforms.
These systems differ in their methods for patient tracking,
as well as their ability to perform various types of modern
radiotherapy advancements, such as image-guided radio-
therapy (IGRT) and intensity-modulated SRS (IMSRS).
However, only limited clinical data on the use of these
systems for intracranial metastatic disease has been
reported [8–12]. Moreover, even fewer studies have pro-
vided data speciﬁcally on linac-based frameless devices
[10, 11]. As the ultimate validation of a new procedure is
measured in terms of clinical outcomes, it is important to
provide treatment data from actual patients prior to wide-
spread acceptance.
In 2005, the University of California at San Diego
adopted an optically-guided linac-based frameless SRS
system (Varian Triology, Varian Oncology Systems, Palo
Alto, CA), which has been used to treat over 200 patients
with either metastatic or primary CNS disease. In this
paper, we describe our clinical experience using optically-
guided frameless SRS to manage brain metastases.
Materials and methods
Patient selection
All patients were treated at the University of California at
San Diego in the Rebecca and John Moores Comprehensive
CancerCenterbetweenDecember2005andJune2008using
frameless SRS. Patients with intracranial metastatic disease
that was histologically veriﬁed at either the primary or
metastatic site were selected for treatment if they were not
surgical candidates and were able to lie still and tolerate
simulation. Initially, patients with greater than four metas-
tases were offered frameless SRS only if they had refused
whole-brain radiotherapy (WBRT), however we transi-
tioned to treating patients with greater than four metastases
after our initial clinical experiences were encouraging.
Patient and treatment characteristics
A total of 65 patients with 204 lesions were treated for
intracranial metastatic disease. Patient characteristics are
summarized in Table 1. The largest tumor diameter was
measured for each lesion, and the median value was 9 mm
(range, 1–35 mm). Prescription dose was 14–22 Gy
(median, 18 Gy) and was given in a single fraction. Spe-
ciﬁc doses were determined by the RTOG 90-05 report
[13]. Radiation therapy was delivered in rotational arc
beams with circular cone collimation in 37 patients (57%)
who had both small and few (three or fewer) lesions. For
patients with either a large and irregular tumor or with
multiple lesions (28 patients, 43%), IMSRS with a dynamic
multi-leaf collimator (MLC) was used. Treatment charac-
teristics are summarized in Table 2. Frameless SRS was
performed with upfront WBRT in 10 patients (15%). Sal-
vage therapy was offered to patients with recurrent local
disease or new intracranial metastases and consisted of
repeated frameless SRS, WBRT or surgery.
Frameless radiosurgery procedure
After obtaining informed consent, patients underwent con-
trast-enhanced T1-weighted magnetic resonance imaging
(MRI) (26 cm FOV, 512 9 512 pixel size, 1.5 mm slice
intervals) using a 3.0 Tesla MRI (General Electric,Fairﬁeld,
CT). Subsequently, customized immobilization was then
designed for each patient and consisted of an Accuform
TM
(CIVCO Medical Solutions, Kalona, IA) headrest ﬁtted to
the patient’s head in neutral position, a molded thermo-
plastic face mask, and a customized bite block.
After the bite-block had been fashioned, the patient was
taken to the treatment vault for veriﬁcation. In the vault,
the patient was ﬁtted with a head band that had an attached
set of reference markers. The bite-block was then removed
and replaced 10 times and the positioning error was mea-
sured each time through the optical-guidance apparatus. If
Table 1 Patient characteristics
Number (%)
Total patients 65
Total lesions 204
Sex
Male 27 (41)
Female 38 (59)
Age
Median 58
Range 20–83
Primary tumor
Lung 28 (44)
Breast 20 (31)
Melanoma 12 (18)
Ovarian 2 (3)
Other 3 (4)
Number of isocenters
Median 1
Range 1–5
Dose (Gy)
Median 18
Range 14–22
Lesions per patient
Median 2
Range 1–13
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the bite block was accepted for use.
Patients were then simulated supine with the thermo-
plastic mask, headrest, and bite block in place using non-
contrast brain computed tomography (CT) (35 cm FOV,
512 9 512 pixel size, 1.25 mm slice intervals). An initial
review of the CT was performed to ensure that all ﬁducial
markers were visible and that no signiﬁcant motion
abnormality occurred. The MRI and CT were then trans-
ferred to the planning center and fused using a rigid auto-
registration tool and subsequently manually veriﬁed.
Planning was performed using Varian FastPlan
 soft-
ware for cone-based plans or Varian Eclipse
TM software
for IMSRS plans and was based on the enhancing tumor
volume with an additional 1–2 mm margin. Single and
multiple isocenter plans were constructed for one or more
lesions under the guidance of the radiation oncologist,
neurosurgeon, and medical physicist. The 80% isodose
curve was selected for each patient planned with cone-
based collimation, and approximately the 90% isodose line
was selected for IMSRS patients.
On treatment day, patient setup and isocenter localiza-
tion were performed with the optical-guidance system. In
addition, a pair of orthogonal kilovoltage (kV) images were
taken and compared to digitally reconstructed radiographs
(DRRs) generated from the planning CT. These images
were used for veriﬁcation purposes only and were not used
for repositioning. Radiation was generated from a Varian
Trilogy linear accelerator (linac) using the 6MV radiosur-
gery mode. Treatment times were generally less than
45 min or up to 1 h if including patient setup time.
Follow-up, statistical analysis and toxicity
Patients were routinely seen 1 week following SRS for a
clinical exam. Contrast-enhanced MRI and physician
evaluation was performed every 3 months until 18 months,
and then routine surveillance was determined on a case-by-
case basis. Treatment response was analyzed by survival
and local control. Local control was deﬁned as the absence
of progression; progression was deﬁned as an increase of
greater than 20% of the sum of the two largest diameters of
the lesion. Intracranial status was deemed as unknown if at
least one follow-up imaging exam was not performed.
These patients were excluded from local control data,
however they were included in survival analysis. Of those
with radiographic follow-up, imaging included MRI (92%)
and CT (8%). Each MRI was independently evaluated for
progression by a radiologist, a radiation oncologist, and a
neurosurgeon. Elsewhere-brain failure was deﬁned as new
intracranial metastatic disease occurring outside of the
treatment volume on radiographic examination, and
regional control was deﬁned as the absence of elsewhere-
brain failure on follow-up imaging. Survival, local failure,
and regional control were estimated by the Kaplan–Meier
method. All statistical analyses were performed using
NCSS (originally, Number Cruncher Statistical System)
(NCSS LLC, Kaysville, UT). Toxicity was graded
according to the Radiation Therapy Oncology Group
(RTOG) scale [14].
Results
The median follow-up for all patients was 6.2 months
(range, 0.13–32.4). Sixteen were alive at the time of
analysis and had a median follow-up of 18.1 months (range
7.5–32.4). The 12-month actuarial survival for the entire
group was 40% [95% conﬁdence interval (CI), 28–52%)
(Fig. 1). No statistically signiﬁcant difference in survival
between patients treated with frameless SRS alone or
combined with WBRT was detected (12-month actuarial
survival 39% vs. 46%, P = 0.40).
Seventeen patients were excluded from local control and
regional control analysis owing to unknown intracranial
status at the time of death. Of the 48 remaining patients
with 135 lesions who were radiographically evaluable for
local control, 37 patients (77%) and 119 lesions (88%) did
Table 2 Treatment characteristics
Treatment type Number of Pts (%)
SRS alone 53 (81.5)
SRS ? WBRT 9 (14.0)
Sx ? SRS 1 (1.5)
Br ? SRS 1 (1.5)
Br ? SRS ? WBRT 1 (1.5)
Total 65 (100)
Pts patients, Sx surgery, Br intracavitary brachytherapy, SRS stereo-
tactic radiosurgery, WBRT whole brain radiotherapy
Fig. 1 Overall survival for all patients treated with frameless SRS
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123not show evidence of progression. Actuarial 12 month
local control was 76% (95% CI, 66–86%) (Fig. 2). Tumors
B2 cm in size had a better 12 month local control rate than
those [2 cm (81% vs. 36%, P = 0.017) (Fig. 3). No sta-
tistically signiﬁcant difference was observed between
lesions treated with and without WBRT (P = 0.31).
Elsewhere-brain failures were detected in 23 patients
(48%). Actuarial 12 month regional control was 46% (95%
CI, 30–62%) (Fig. 4). No statistically signiﬁcant difference
in regional control was observed between patients treated
with and without WBRT (P = 0.83). Salvage therapy was
performed for patients with local failures or new intracra-
nial metastatic disease and consisted of repeat SRS (nine
patients, 14%), WBRT (seven patients, 11%), repeat SRS
and WBRT (three patients, 5%), and surgery (two patients,
3%). Of patients treated with repeat SRS, nine patients
received a single re-treatment, two patients received two
re-treatments, and one patient received four re-treatments.
Nine patients (14%) had grade 2 toxicities; one patient
had a single seizure, one patient had transient mild ataxia,
and seven had edema-associated symptoms that resolved
with steroids. Grade 3 or higher toxicities occurred in three
patients (5%); one patient developed aphasia, one patient
with metastatic melanoma developed hemorrhage in a
treated lesion, and one patient developed hemiparesis
secondary to radionecrosis and required surgery.
Discussion
Frameless SRS is a relatively new treatment that avoids the
use of invasive head frames for patient immobilization and
provides several distinct advantages over frame-based
techniques. Although several systems are currently in use,
limited clinical data exist to demonstrate the safety and
efﬁcacy of frameless devices, and data are especially
lacking on systems that employ conventional linac-based
platforms. In this study, we present encouraging clinical
outcomes on a series of patients treated with optically-
guided frameless linac-based SRS for the management of
brain metastases.
Local control was selected as a primary endpoint, as it is
a sensitive clinical outcome for assessing targeting accu-
racy. Frame-based SRS has been shown to produce
12-month actuarial local-control rates ranging from 64 to
89% (Table 3)[ 4, 15–21]. Our actuarial local control rate
was 76% at 12 months, which compares favorably to
frame-based, as well as other frameless SRS techniques
(Table 3). Furthermore, a unique advantage of the present
series of patients is that the majority of our patients (82%)
did not receive upfront WBRT or surgery, and therefore the
inﬂuence of WBRT and other initial therapies on our local
control rate was minimized. In contrast, other frameless
Fig. 2 Local control for patients treated with frameless SRS
Fig. 3 Local control stratiﬁed by tumors B2c m( solid line) and
[2c m( dashed line)
Fig. 4 Regional control for patients treated with frameless SRS
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treated with frameless SRS alone.
Survival was also analyzed as an endpoint. Frame-based
SRS 12-month actuarial survival rates range from 23 to
54% (Table 3). Our experience with frameless SRS resul-
ted in a 12 month actuarial survival rate of 40%, which
also compares favorably to both frame-based, as well as
other frameless SRS techniques (Table 3).
Frameless techniques have several advantages over
frame-based approaches, including added patient comfort,
convenience of use, and improved ability to perform hyp-
ofractionated therapy for large lesions. Generally, SRS is
recommended for lesions less than 3 cm [22]. However,
research has suggested that patients may beneﬁt from
hypofractionated SRS for larger tumors [9, 23]. Although
hypofractionation is possible with frame-based systems,
frameless systems can offer improved patient comfort and
less complicated delivery of therapy.
Clinical outcomes have now been reported on each of the
frameless radiosurgery systems currently available. Cyber-
Knife
 offers a frameless system that employs a compact
linac mounted on a robotic-arm that acquires X-ray based
images for precise target localization [24]. Novalis
TM
(BrainLab Inc, Chicago, IL) offers a system that uses both
optical-guidance of reﬂective ﬁducials placed over the
patient’s mask for initial positioning and orthogonal kilo-
voltage images for added image-guidance [11]. RadioCa-
meras (Zmed, Ashland, MA) provides a linac-based system
that employs an optically-guided bite-block [10], which was
later adapted by Varian and combined with the Trilogy
TM
machine to allow for high-output delivery along with IGRT
and IMSRS. Clinical outcomes reported by these systems
are similar (Table 3), and the advantages of each technique
depend on various institutional preferences.
Although these results are promising, our analysis has
several limitations. First, this is a retrospective study and
thus suffers from the inherent limitations of such an anal-
ysis. Second, not all patients underwent follow-up imaging
to document local control, and therefore, local failures may
have been missed. Unfortunately, this is a common prob-
lem with research on brain metastases, as many patients die
within a few months of treatment.
In conclusion, we report on our clinical experience using
an optically-guided linac-based frameless SRS system for
the treatment of brain metastases. Our results show
encouraging clinical outcomes that compare favorably to
Table 3 Comparison of survival and local control rates between frame-based and frameless SRS in non-randomized studies on brain metastases
Study (year) Pts Treatment system Crude LC (%) Actuarial 1-year LC (%) Actuarial 1-year survival (%)
Frame-based SRS
Becker [15]5 5 Linac-based 92 61 33
Sneed [4] 268 Gamma Knife
a -- 38
Chitapanarux [16]4 1 Linac-based 76
b 68 48
Datta [17]5 3 Gamma Knife 89 - 23
Schomas [19]8 0 Linac-based 91 89 33
Bhatnagar [20] 205 Gamma Knife - 71 37
c
Rades [18]9 4 Linac-based
d - 64 54
Serizawa [21] 2,390 Gamma Knife -- 30
c
Frameless SRS
Shimamoto [8]4 1 CyberKnife
 - 80
e 26
f
Kamath [10]6 4 Linac-based 88
b 40
c,g 38
c
Nishizaki [9]7 1 CyberKnife
 83 - 47
Breneman [11]5 3 Linac-based - 80 44
Nath (present series) 65 Linac-based 88 76 40
–, not reported
Pts patients, LC local control
a 76% Gamma Knife and 24% linac-based
b By patient
c Estimated from Kaplan–Meier curve
d 71% linac-based and 29% Gamma Knife
e Freedom from progression for patients treated with C24 Gy
f For patients treated with C24 Gy
g Local control determined by patient
J Neurooncol (2010) 97:67–72 71
123traditional frame-based as well as other frameless tech-
nologies and support the continued role of frameless SRS
in the management of patients with brain metastases.
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